These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 30227916

  • 1. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, Cossais S, Roudot-Thoraval F, Canva V, Mathurin P, Dhumeaux D, Yazdanpanah Y.
    J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
    Deuffic-Burban S, Obach D, Canva V, Pol S, Roudot-Thoraval F, Dhumeaux D, Mathurin P, Yazdanpanah Y.
    J Viral Hepat; 2016 Oct; 23(10):767-79. PubMed ID: 27144512
    [Abstract] [Full Text] [Related]

  • 3. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
    Eckman MH, Ward JW, Sherman KE.
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA, Chung W, Choi HY, Ki M, Jang ES, Jeong SH.
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [Abstract] [Full Text] [Related]

  • 5. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Marcellusi A, Viti R, Damele F, Cammà C, Taliani G, Mennini FS.
    Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Mabileau G, Dhersin JS, Yazdanpanah Y.
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C, Rossol S, Ortsäter G, Kautz A, Krüger K, Herder B, Stahmeyer JT.
    BMC Infect Dis; 2019 Dec 02; 19(1):1019. PubMed ID: 31791253
    [Abstract] [Full Text] [Related]

  • 11. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
    Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, Rota M, Cesana G, Mantovani LG, Annoni G, Strazzabosco M.
    Liver Int; 2017 Jul 02; 37(7):982-994. PubMed ID: 27943549
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States.
    Tatar M, Keeshin SW, Mailliard M, Wilson FA.
    JAMA Netw Open; 2020 Sep 01; 3(9):e2015756. PubMed ID: 32880650
    [Abstract] [Full Text] [Related]

  • 13. A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective.
    Kim HL, Kim KA, Choi GH, Jang ES, Ki M, Choi HY, Jeong SH.
    Clin Mol Hepatol; 2022 Jan 01; 28(1):91-104. PubMed ID: 34736311
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
    Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A, WEF Study Group.
    J Hepatol; 2013 Oct 01; 59(4):658-66. PubMed ID: 23707373
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, Patel KK, Green J.
    Pharmacoeconomics; 2004 Oct 01; 22(4):257-65. PubMed ID: 14974875
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
    Su S, Wong WC, Zou Z, Cheng DD, Ong JJ, Chan P, Ji F, Yuen MF, Zhuang G, Seto WK, Zhang L.
    Lancet Glob Health; 2022 Feb 01; 10(2):e278-e287. PubMed ID: 35063115
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.
    Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed MK, Yazdanpanah Y.
    Clin Infect Dis; 2014 Apr 01; 58(8):1064-71. PubMed ID: 24510934
    [Abstract] [Full Text] [Related]

  • 18. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
    Kim DY, Han KH, Jun B, Kim TH, Park S, Ward T, Webster S, McEwan P.
    PLoS One; 2017 Apr 01; 12(1):e0167770. PubMed ID: 28060834
    [Abstract] [Full Text] [Related]

  • 19. Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation.
    Fang K, Wang HL, Lin Y, Zheng L, Li S, Wu J.
    Public Health; 2024 Mar 01; 228():186-193. PubMed ID: 38387115
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A, Martel MJ, Tahami Monfared AA, Goeree R.
    J Med Econ; 2016 Mar 01; 19(2):181-92. PubMed ID: 26453248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.